WBG
IDNA icon

Wharton Business Group’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Wharton Business Group’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.84M Sell
269,987
-3,160
-1% -$91.7K 0.3% 50
2025
Q4 		$7.15M Sell
273,147
-12,630
-4% -$325K 0.27% 51
2025
Q3 		$6.75M Sell
285,777
-4,950
-2% -$109K 0.29% 49
2025
Q2 		$5.96M Buy
290,727
+5,255
+2% +$106K 0.25% 51
2025
Q1 		$5.85M Buy
285,472
+14,855
+5% +$332K 0.26% 50
2024
Q4 		$6.12M Sell
270,617
-282
-0.1% -$6.77K 0.28% 52
2024
Q3 		$6.67M Hold
270,899
– – 0.3% 52
2024
Q2 		$6.26M Buy
270,899
+1,345
+0.5% +$31.5K 0.32% 51
2024
Q1 		$6.49M Buy
269,554
+68,890
+34% +$1.61M 0.31% 49
2023
Q4 		$4.62M Sell
200,664
-82,700
-29% -$1.66M 0.23% 54
2023
Q3 		$5.77M Buy
283,364
+20,014
+8% +$449K 0.32% 53
2023
Q2 		$6.15M Sell
263,350
-44,150
-14% -$1.06M 0.41% 44
2023
Q1 		$7.16M Buy
307,500
+152,195
+98% +$3.81M 0.43% 43
2022
Q4 		$3.91M Sell
155,305
-150,600
-49% -$4.05M 0.23% 59
2022
Q3 		$8.07M Buy
305,905
+6,030
+2% +$186K 0.55% 36
2022
Q2 		$8.67M Buy
299,875
+75,305
+34% +$2.25M 0.57% 36
2022
Q1 		$7.74M Buy
224,570
+86,435
+63% +$3.05M 0.47% 37
2021
Q4 		$6.05M Sell
138,135
-22,860
-14% -$1.08M 0.37% 44
2021
Q3 		$8.16M Sell
160,995
-1,895
-1% -$98.8K 0.83% 18
2021
Q2 		$8.47M Buy
162,890
+44,155
+37% +$2.07M 0.66% 31
2021
Q1 		$5.43M Buy
118,735
+97,625
+462% +$4.77M 0.42% 38
2020
Q4 		$970K Sell
21,110
-195
-0.9% -$8.42K 0.08% 60
2020
Q3 		$830K Buy
21,305
+3,355
+19% +$129K 0.08% 58
2020
Q2 		$682K Buy
+17,950
New +$606K 0.07% 61

Other funds holding IDNA

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

Wharton Business Group's IDNA Position: Q1 2026 in Review

Wharton Business Group reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 1.2% in Q1 2026, selling an estimated $91.7K and leaving 269,987 shares worth $7.84M. The position accounts for 0.3% of the portfolio, ranked #50.

Wharton Business Group first reported a position in IDNA in Q2 2020 and has held it in 24 quarters since. The position peaked at $8.67M in Q2 2022. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

  • Wharton Business Group held 269,987 shares of iShares Genomics Immunology and Healthcare ETF worth $7.84M as of Q1 2026.
  • Wharton Business Group sold 3,160 iShares Genomics Immunology and Healthcare ETF shares in Q1 2026, an estimated $91.7K.
  • iShares Genomics Immunology and Healthcare ETF made up 0.3% of Wharton Business Group's portfolio in Q1 2026, its #50 holding.
  • Wharton Business Group first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2020 and has held it in 24 quarters since.
  • Wharton Business Group's iShares Genomics Immunology and Healthcare ETF position peaked at $8.67M in Q2 2022.
  • 60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Wharton Business Group's 13F filing for Q1 2026, filed 7 May 2026.